News

KMC-BRE-WSI-(60-of-60)
0

Marathon Runner Raises Over £650 In Memory Of Adrian King

Seasoned runner Mike, recently took part in the London Marathon and raised an incredible£658.25 for Bright Red in memory of his friend Adrian King.

Mike is a member of the Darlington Harriers and found out he had a space in the marathon on New Years Day. Despite not having as long to train as he would like, and picking up a hamstring injury on the 14th mile, he managed to complete the course.

He took some time out of his day to come and visit the staff on Ward 33, to say thank you for the fantastic care the staff gave his good friend Adrian.

Sister Jill Phelan explained ‘It’s thanks to the wonderful generosity of people like Mike that we’re able to go the extra mile for patients. We are extremely grateful for all his efforts and promise to put the funds to good use!’

Marathon runner Mike, with Julie King and staff from Ward 33

Marathon runner Mike, with Julie King and staff from Ward 33

nerg 2017 1
0

NERG 2017 Raffle Tickets Now On Sale

Tickets are now on sale for NERG’s annual raffle!

The top prizes up for grabs are :

1st prize – Nintendo Switch and games bundle(Zelda & Mario Kart)
2nd prize – 3DS XL Fire Emblem: Fates Edition (Includes Fire Emblem
Game)
3rd prize – Assassins Creed: Black Flag – Black Beard limited edition
statue
4th Prize – Assassins Creed: Black Flag – Edward Kenway limited
edition
statue
5th Prize – Art of Atari book
6th Prize – Yo-Kai Watch 2 – 3DS game

Plus many, many more to be added on the day.

All funds raised from the sale of these tickets are donated to Bright Red to help fight blood cancer for a brighter future!

To be in with a chance of winning, all you need to do is buy a ticket!

 


Quantity




KMC-BRE-WSI-(53-of-60)
0

Happy Anniversary Mark!

This month our Chairman, Mark Thompson, celebrates his 10th Anniversary with Bright Red.

Motivated by his wife’s lymphoma diagnosis, Mark joined the charity when it was still known as Marrow and Stem Cell Transplant 2000. Utilising his vast business experience, he set about improving our structure and raising our profile – whilst simultaneously maintaining our local charity feel.
Mark saw the true potential of the charity, leading us through our rebrand to Bright Red and managing the expansion of our objectives, to include investments in patient care and staff development alongside research.

Under Mark’s leadership we agreed to our largest grant to date and purchased a state of the art Cytometer machine. We also helped fund the new ECP treatment centre, created Lee Robson Patient Care Grants, employed our first nurse (second on the way) and much, much more.

I have learned such a great deal under his management and have been consistently motivated by his undying enthusiasm to make the north the safest place to be for blood cancer patients. It is no exaggeration to say that we wouldn’t be anywhere near where we are without his leadership & we hope to follow his example for many years to come.

Happy Anniversary, Mark! Thank you for all that you do.

Ashley, Charity Manager

 

Professor Matt Collin & Chairman Mark Thompson with the state of the art Cytometer machine.

Professor Matt Collin & Chairman Mark Thompson with the state of the art Cytometer machine.

 

18120186_10154521679314142_641520805_o
0

Vegas Night Raises £3,400

Maria Potts recently hosted a Vegas night at The Dead Rabbit in Sunderland and raised an incredible £3,400 for our charity.

Maria said “After reflecting on the brilliant night, where we raised over £3,400, I feel exceptionally privileged that my friends, family and complete strangers took part in raising this amazing sum as well as something which is priceless to me: awareness of a charity which is now so close to my heart. We hope the pictures from the night demonstrates the hard work and time we put into the night.”

To raise this impressive sum in one evening shows just how much time and dedication Maria put into fundraising. We are eternally grateful to Maria and everyone else involved. Thank you for helping us fight blood cancer for a brighter future!

Here are a few photos from the night:

18159633_10154521679494142_240083725_o18159545_10154521679484142_256709134_o

 

 

 

 

 

18120459_10154521679724142_328150647_o18109912_10154521678949142_1571568222_o

Tyneside 10k
0

Andrew’s April Running Challenge

Through our work, we are lucky to meet some amazing people, who go above and beyond to raise vital funds to ensure we can continue improving the lives and treatment of people in the north who are dealing with blood cancer.

One of these amazing people, is Andrew. Andrew set himself a number of running challenges throughout April to raise funds for Bright Red.

Andrew said “After my mum was diagnosed with Leukaemia in the run up to Christmas I set myself the challenge of raising money for Bright Red. So throughout April I tackled a series of runs including a 5k, a 10k, a half marathon, full marathon culminating in a 47 mile ultra-marathon through Northumberland. There were long lonely stretches of the run that left me with just my thoughts for company, and I thought long and hard about why I was doing it. The pain and discomfort I felt was nothing compared to what other people experience and knowing this helped me get to the end in 9 hours 22 minutes.  Bright Red do amazing work supporting cancer patients and their families and I was privileged to be able to help them in my own small way.”

Andrew’s fundraising total stands at an incredibly £1,137 – a sum which will go a long way in our fight against blood cancer.

https://www.justgiving.com/fundraising/AndrewMcFetrich80

IMG_5134
0

Santander Support Bright Red

We want to say a huge thank you to Santander for supporting our new project ‘Managing Finances Through Cancer’. The Santander Community Fund recently donated £5,000 towards the project, which will enable us to host several courses right across our region.

We look forward to sharing more information with you all shortly.

Jpeg
2

Phillips family & friends continue their support of Bright Red

We have recently received another £1,500 in donations from Kath Phillips and her dear friends.

They raised this impressive sum through their regular Come Dine With Me event and taking on the Seaham Boxing Day dip.

We are extremely grateful for all they continue to do for our charity, we wouldn’t be able to do as much as we can without this kind of support. Every £1 truly makes a difference to blood cancer patients in the north.

Kath said “I want to say a big thank you to all our friends who have supported us as a family and the Bright Red Charity in memory of our son Christopher.”

Here are a few photos from their fundraising efforts!

KMC-BRE-WSI-(59-of-60)
0

Newcastle business community celebrates another successful Oktoberfest

Property consultants Bilfinger GVA and international design practice, Ryder Architecture joined together once again to sponsor the third year annual Oktoberfest on 20 October at the new home of Wylam Brewery, in Exhibition Park, Newcastle.

The charity evening was attended by over 550 clients, professionals and members of the North East business community with all proceeds being split between two charities – Bright Red and Alzheimer’s Society.

Guests enjoyed a fun filled evening, sampling appropriate Oktoberfest food and drink whilst being entertained by local band, Groove Train.  There was a host of opportunities throughout the evening to take part in raffles, silent auctions and to buy specialist ales to further support these fantastic charities.

The event sponsors built upon last years’ success and raised over £2,000 for each charity on the evening.  Tom Baker of Bilfinger GVA commented, “It’s always a fantastic evening which attracts an amazing number of guests.  Most importantly we’ve raised lots of money two worthy charities”.

Jonathan Seebacher, architectural director at Ryder added, “We’re very proud to sponsor the evening again – the volume of people and money raised is testament to the North East property and development community.  We are delighted with the success of the event”.

This donation has been one of many from the team at Ryder. Ryder have been a major support to Bright Red over the years and we continue to be overwhelmed by all that they do. We are so thankful that they have been part of our journey and truly wouldn’t be where we are today without them.

Valentine Raffle

Our good friends at Daniel Farmshop in Wylam are hosting a Valentine’s Raffle to raise funds for us.

If you’ve ever been there you’ll know how fantastic the place is – if you haven’t been, you’re missing out!

Top prize is a Fenwicks spirit hamper worth over £100, runners up prizes include £50 gift hamper, £30 Meat voucher, Afternoon Tea for Two and a box of chocolates.

Tickets are £1 each. The draw takes place on Tuesday 14 February at noon.

img_3279

Quantity



KMC-BRE-WSI-(37-of-60)
0

58th ASH Annual Meeting & Exposition

The 58th American Society of Hematology Meeting & Exposition took place over the 3rd – 6th December. We were delighted to be able to support Carmela Ciardullo with a Bright Red travel grant.

Carmela is a Research Associate at the Northern Insitute for Cancer Research, and was invited to present her abstract focusing on Chronic Lymphocytic Leukaemia.

Carmela said “ASH 2016 was an invaluable experience with thousands of delegates attending and numerous high quality oral and poster presentations. The excellent education program provided an opportunity to learn about research outside my normal field of interest and the scientific committee sessions as always provided up to the minute insights into a range of topics.

Of particular interest to me were both oral and poster presentations regarding novel MDM2 antagonists as a treatment options for patients with haematological malignancies. Christian Klein from Roche Innovation Center Zurich discussed their preclinical data demonstrating a strong anti-tumoral efficacy of combining the CD20 antibody obinutuzumab with the Bcl-2 inhibitor venetoclax and the MDM2 inhibitor RG7388. Their data showed that the triple combination of obinutuzumab with venetoclax and RG7388 can further improve outcome in two preclinical human wildtype p53 NHL tumor xenograft models, in particular regarding complete tumor remissions and long term response, and support the clinical investigation of this triple combination for the treatment of B cell malignancies.

Another study by William Pierceall showed that multiparametric flow cytometry MRD assessment is an early indication aligning with cCR in relapsed/refractory AML patients treated with RG7388. Further, assessment for association with progression-free survival indicated that the lowest quartile patients by MRD flow cytometry measurement (<1%) are likely to exhibit a pronounced survival benefit over those patients with higher detectable levels of MRD (>1%). As such, the data presented support inclusion of MRD assessment by flow cytometry as a prognostic indicator to provide guiding information for assignment of depth of AML patient response. This biomarker for diagnostic potential and prognostic indicator of survival-based outcomes should be monitored in future randomized clinical studies of RG7388.

Another study from MD Anderson Cancer Center reported the initial results of a Phase I trial aimed at characterizing the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles and preliminary efficacy of the MDM2 antagonist DS3032b in in patients with hematological malignancies.

However, a clinical challenge is that not all the tumors bearing wild-type TP53 are sensitive to MDM2 inhibition. In this respect, a group from MDM Anderson Cancer Center discovered novel gene profiling-based algorithms for predicting tumor sensitivity to MDM2 inhibition using DS-3032b, a novel potent MDM2 inhibitor, which is currently in early clinical trials.

Of particular interest to me were the presentations regarding novel treatment options for patients with chronic lymphocytic leukemia, as well as the numerous updates on CLL genomics and epigenomics. I also had the amazing opportunity to present my abstract entitled “The p53-MDM2 Antagonist RG7388 Activates p53 and Induces a Predominantly Pro-Apoptotic Gene Expression Signature in Chronic Lymphocytic Leukemia” and I had useful and positive feedback.

Overall ASH 2016 was an excellent experience. Many thanks to Bright Red for the Travel Award and for supporting my participation to this meeting.”

Enter your pledge amount

£

Add to Cart